Thalidomide 100MG
Ended Awarded
- Contract number
- 36C24526N0312
- Awardee
-
Bristol-Myers Squibb Company UEI UFGKB2B71N12
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $5,814
Award facts
- Contract value 100% obligated
- $5,814.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38141, USA
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order to Bristol-Myers Squibb Company for thalidomide 100 mg with a contract value of $5,814.24 under a firm fixed-price arrangement. The award was issued on February 10, 2026, with an ultimate completion date of February 13, 2026, and carries no set-aside designation. This delivery order represents a call against Bristol-Myers Squibb's existing Federal Supply Schedule contract (FSS-61-IB: Pharmaceuticals and Drugs), which carries a substantial ceiling value of $12.3 billion and extends through April 30, 2029. The performance location is identified as Memphis, Tennessee.
Bristol-Myers Squibb, a global biopharmaceutical manufacturer headquartered in Lawrenceville, New Jersey, serves as a critical supplier to the VA healthcare system, with a specialized focus on oncology, immunotherapy, and cell therapy products. The company has received more than fifty documented delivery orders from the VA since 2022, with sustained demand across multiple Veterans Integrated Service Networks for advanced cancer treatments and transplant-related therapies. Thalidomide, the product being supplied under this order, is a specialized pharmaceutical commonly utilized in the treatment of certain hematologic malignancies and multiple myeloma, reflecting the VA's commitment to providing state-of-the-art oncology care to eligible veterans.
Quick answers
Who was awarded contract 36C24526N0312?
36C24526N0312 was awarded to Bristol-Myers Squibb Company by Veterans Integrated Service Network 5 (Veterans Health Administration) on February 10, 2026.
How much is contract 36C24526N0312 worth?
The government has obligated $5,814 on 36C24526N0312.
Is contract 36C24526N0312 an order under another contract?
Yes. 36C24526N0312 is a BPA call under 36F79724D0101-36E79726A0010, a blanket purchase agreement, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0312 competed?
The extent of competition for 36C24526N0312 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award